Autologous Cell Therapies: New Developments in Cell-Based Immunotherapy

19 Jan 2023
15:30
Modalities and Indications Track
SPONSORED BY
TrakCel

3:30pm Chair Introduction

Bruce Levine, Professor, Cancer Gene Therapy, University of Pennsylvania

 

3:35pm Presentation: Evolution, Revolution: How Adaptimmune is Developing the Next Generation of TCR T-Cell Therapies Against Solid Tumors

  • Exploring Adaptimmune’s MAGE A4 franchise from the first gen product Afamicel on a path commercialisation to the next gen product ADP-A2M4CD8 increasing signals across multiple indications
  • How clinical and translational learnings feed from one to the other and influence trial design

Joanne Brewer, Chief Scientific Officer, AdaptImmune

 

3:50pm Presentation: The Practicalities and Pitfalls of Orchestrating Autologous Therapies

  • An insight into first hand case studies, focusing directly on orchestration implementation
  • A deep dive into the best practice of orchestrating Autologous therapies, and what to avoid during implementation

Matthew Lakelin, Vice President, Scientific Affairs, Product Development & Co-Founder, TrakCel

 

4:05pm Presentation: TBA

Frank Boriello, Chief Executive Officer, Alloplex Biotherapeutics

 

4:20pm Presentation: Novel Targets for Autologous CAR-T Therapies in Solid Tumors

  • To date, autologous cell therapies have not demonstrated clear or broad clinical success in solid tumors
  • Effective solid tumor targeting with autologous CAR-T therapies demands actionable targets, active constructs and smart clinical approaches

Jason Litten, Chief Medical Officer, Chimeric Therapeutics

 

4:35pm Presentation TBA

Friedrich Graf Finckenstein, Chief Medical Officer, Iovance

 

4:50pm Presenter Q&A

With all session participants

Speakers

Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy; President, International Society for Cell & Gene Therapy
University of Pennsylvania
Frank Borriello
Chief Executive Officer
Alloplex Bio
Friedrich Graf Finckenstein
Chief Medical Officer
Iovance Biotherapeutics Inc
Jason B. Litten
Chief Medical Officer
Chimeric Therapeutics
Joanne Brewer
Chief Scientific Officer
AdaptImmune